This study looked at the effectiveness and safety of taking firmonertinib and anlotinib together. It involved 36 adults with locally advanced or metastatic non-small cell lung cancer that had specific EGFR mutations. Participants took the oral medications on a 21-day cycle. The median follow-up time was about 19.4 months.
The main results showed that 63.9% of patients had a tumor response, and 100% had disease control. The median time before the cancer grew again was 19.6 months, and responses lasted an average of 23.0 months. The study also found that having a TP53 mutation might be linked to a worse outcome, though this finding was not statistically certain.
Safety was generally manageable, with diarrhea and high blood pressure being the most common side effects. About one-third of patients stopped the treatment for various reasons. Readers should understand that this is a Phase I/II trial with a small group of people. These early findings are promising but need to be confirmed by larger, more rigorous studies before changing standard care.